Zacks: Analysts Anticipate Kamada Ltd. (NASDAQ:KMDA) Will Post Earnings of $0.12 Per Share

Wall Street analysts expect that Kamada Ltd. (NASDAQ:KMDA) will announce $0.12 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Kamada’s earnings, with the highest EPS estimate coming in at $0.12 and the lowest estimate coming in at $0.11. Kamada reported earnings per share of $0.16 in the same quarter last year, which would suggest a negative year over year growth rate of 25%. The company is expected to announce its next quarterly earnings results on Tuesday, August 4th.

According to Zacks, analysts expect that Kamada will report full-year earnings of $0.37 per share for the current financial year, with EPS estimates ranging from $0.31 to $0.43. For the next fiscal year, analysts forecast that the firm will post earnings of ($0.04) per share, with EPS estimates ranging from ($0.05) to ($0.03). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Kamada.

A number of research firms recently weighed in on KMDA. Zacks Investment Research cut shares of Kamada from a “buy” rating to a “hold” rating in a research report on Tuesday, June 23rd. ValuEngine raised shares of Kamada from a “sell” rating to a “hold” rating in a research report on Tuesday, June 23rd. BidaskClub raised shares of Kamada from a “hold” rating to a “buy” rating in a research report on Thursday, June 18th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Kamada in a research report on Tuesday, May 19th. Finally, TheStreet raised shares of Kamada from a “c+” rating to a “b-” rating in a research report on Wednesday, May 20th. Two analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $10.00.

A number of hedge funds have recently modified their holdings of KMDA. Ritholtz Wealth Management purchased a new position in Kamada in the 1st quarter valued at approximately $69,000. Seizert Capital Partners LLC acquired a new stake in shares of Kamada in the 4th quarter valued at $194,000. James Investment Research Inc. acquired a new stake in shares of Kamada in the 1st quarter valued at $255,000. Marshall Wace LLP acquired a new stake in shares of Kamada in the 1st quarter valued at $276,000. Finally, ETF Managers Group LLC raised its holdings in shares of Kamada by 9.7% in the 1st quarter. ETF Managers Group LLC now owns 49,399 shares of the biotechnology company’s stock valued at $278,000 after purchasing an additional 4,388 shares in the last quarter. 12.91% of the stock is owned by institutional investors.

Shares of NASDAQ KMDA traded down $1.07 during midday trading on Monday, reaching $7.67. 16,493 shares of the stock were exchanged, compared to its average volume of 176,814. The company has a 50 day simple moving average of $7.95 and a 200 day simple moving average of $6.82. The stock has a market capitalization of $389.11 million, a P/E ratio of 14.69 and a beta of 1.25. Kamada has a twelve month low of $4.40 and a twelve month high of $9.91.

About Kamada

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency.

Featured Story: Learning About the VIX – Volatility Index

Get a free copy of the Zacks research report on Kamada (KMDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kamada (NASDAQ:KMDA)

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.